Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Isotretinoin therapy in acne and modern practice
Mark Goodfield
Since its introduction into widespread use in the early 1980s, isotretinoin has been a dramatically successful therapy for severe and persistent acne. Initially used only for severe cystic acne, its use has been gradually extended for those with significant but milder disease that has been persistent despite the use of conventional topical and oral therapies. It has an important role in those with scarring because of their acne, and also in those with dysmorphophobia. Most studies indicate a success rate of almost 100%, and confirm that approximately two-thirds of patients have no relapse when treatment is discontinued. However, it is not clear whether these figures are correct for the patient profile now being treated. The existing licence does not cover current accepted usage.
Dermatology in practice
2004;
12
(1): 6–8
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
UCB announces two-year data for Bimzelx in hidradenitis suppurativa
Sanofi/Regeneron’s Dupixent shows promise in phase 3 chronic spontaneous urticaria study
Merck announces ten-year data for anti-PD-1 therapy Keytruda in melanoma
Eli Lilly receives FDA approval for IL-13 inhibitor Ebglyss in atopic dermatitis
Acelyrin’s izokibep shows promise in phase 3 hidradenitis suppurativa trial
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy